Wave Life Sciences, Inc. - Common Stock (NQ:WVE)

3.815 +0.035 (+0.93%)

Delayed Quote Updated: 11:45 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Wave Life Sciences, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Crude Oil Gains Over 1%; BioVie Shares Plunge ↗

September 24, 2024

Via Benzinga

Nasdaq Surges 100 Points; Thor Industries Earnings Top Views ↗

September 24, 2024

Via Benzinga

Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug ↗

September 24, 2024

Wave Life Sciences reveals positive interim data from its Phase 2 FORWARD-53 study on WVE-N531 for Duchenne muscular dystrophy patients. Results show improved muscle health, dystrophin production, and...

Via Benzinga

Wave Life Sciences, Nio, Li Auto, Tesla And Other Big Stocks Moving Higher On Tuesday ↗

September 24, 2024

Via Benzinga

Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

September 24, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Deep Dive Into WAVE Life Sciences Stock: Analyst Perspectives (4 Ratings) ↗

August 09, 2024

Via Benzinga

Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut

September 20, 2024

Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment.

Via MarketBeat

Topics Economy

Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating ↗

August 14, 2024

William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1...

Via Benzinga

Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy

August 12, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

WVE Stock Earnings: WAVE Life Sciences Misses EPS, Misses Revenue for Q2 2024 ↗

August 08, 2024

WVE stock results show that WAVE Life Sciences missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

What Analysts Are Saying About WAVE Life Sciences Stock ↗

June 26, 2024

Via Benzinga

WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) ↗

May 15, 2024

Via Benzinga

Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

August 08, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024

August 01, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

June 26, 2024

Via Benzinga

What's Going On With Wave Life Sciences Stock On Tuesday? ↗

June 25, 2024

Wave Life Sciences reports Phase 1b/2a SELECT-HD trial results for WVE-003 in Huntington's disease, demonstrates promise as a disease-modifying therapy.

Via Benzinga

Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease

June 25, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing

June 12, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference

May 30, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

WVE Stock Earnings: WAVE Life Sciences Misses EPS, Misses Revenue for Q1 2024 ↗

May 09, 2024

WVE stock results show that WAVE Life Sciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 09, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

May 09, 2024

Appointment builds on Wave’s recent progress advancing innovative genetic targets, such as INHBE, and continues to add significant experience to accelerate the rapid identification and translation of...

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference

May 07, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024

May 02, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)

April 30, 2024

Proof-of-mechanism data for WVE-006 in individuals with AATD remain on track for 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing

April 23, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 04, 2024

Via Benzinga

Wave Life Sciences to Present at Upcoming Investor Conferences

March 27, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

American Eagle Reports Upbeat Earnings, Joins Kroger, Burlington Stores And Other Big Stocks Moving Higher On Thursday ↗

March 07, 2024

U.S. stocks were higher, with the Dow Jones index gaining more than 150 points on Thursday.

Via Benzinga

Topics Stocks

Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

March 07, 2024

Shares of HighPeak Energy, Inc. (NASDAQ: HPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter revenue results.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.